U.S. Markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.31
    -0.05 (-0.10%)
     
  • Gold

    1,836.80
    +6.90 (+0.38%)
     
  • Silver

    25.07
    +0.20 (+0.82%)
     
  • EUR/USD

    1.2092
    +0.0009 (+0.0725%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • Vix

    24.34
    +1.09 (+4.69%)
     
  • GBP/USD

    1.3596
    +0.0010 (+0.0707%)
     
  • USD/JPY

    103.6800
    -0.0070 (-0.0067%)
     
  • BTC-USD

    36,566.22
    +1.28 (+0.00%)
     
  • CMC Crypto 200

    712.01
    -23.13 (-3.15%)
     
  • FTSE 100

    6,720.65
    -15.06 (-0.22%)
     
  • Nikkei 225

    28,507.07
    +264.86 (+0.94%)
     

Cellectis: Monthly Information on Share Capital and Company Voting Rights

·2 min read

(Article 223-16 of General Regulation of the French financial markets authority)

Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS):

Listing market: Euronext Growth
ISIN code: FR0010425595

Date

Total number of shares

in the capital

Total number of voting

rights

01/31/2020

42,465,669

51,246,412

About Cellectis

Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN® is a registered trademark owned by Cellectis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200207005523/en/

Contacts

Media contacts:
Jennifer Moore, VP, Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, ckasunich@kcsa.com

IR contact:
Simon Harnest, VP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com